Biomedical, Clinical & Life Sciences

Susan G. Komen Career Catalyst Research (CCR) Grant FY25

The CCR Grants have fostered promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of “protected time” for research career development under the guidance of a Mentor Committee. The Foundation is especially interested in hypothesis-driven studies that target breast cancer, in the development of strategies for earlier diagnosis, reduce risk of breast cancer, or increase the effectiveness of current therapies to lead to longer and better-quality outcomes for patients.  They may be considered basic, translational, clinical and/or population science. 

Award: Up to $150,000 per year (combined direct and indirect costs) for up to three years ($450,000).

Eligibility:

  • Must have a doctoral degree, such as M.D., Ph.D., Dr.P.H., D.O., or equivalent.
  • Must currently hold a full-time faculty appointment or have a formal offer letter from the Institution that confirms position and start date by the Application due date (October 9, 2024).
  • Must not have held any faculty appointment, including non-tenure and tenure track appointments combined, for more than a total of 6 years by the Application due date.
  • Must not simultaneously hold any other Grant awarded by Susan G. Komen.
  • Must not currently be or have been a Principal Investigator on an existing NIH R01 grant or their equivalent as of the date of Award Notification (on or around April 15, 2025).
  • Must conduct the proposed research and training at the Lead Mentor’s U.S. based institution.
  • Must have adequate space and facilities to conduct the proposed research and must be able to devote at least 75% of full-time effort to breast cancer research and activities.

*The University of Arizona Cancer Center (UACC) can nominate up to two applicants but only if at least one of the two nominees identifies as as someone from groups shown to be historically minoritized and marginalized in biomedical research from National Science Foundation data (details outlined in RFA).

For more information please contact UACC-preaward@arizona.edu

Apply to Internal Competition // Limit: 2 // Tickets Available: 2*

Funding Type
Internal Deadline
External Deadline
August 7, 2024
Solicitation Type

Susan G. Komen Career Transition Award FY25

This grant mechanism aims to help outstanding senior postdoctoral fellows and clinical fellows, working under the guidance of a mentor, launch their competitive, independent breast cancer research careers. Career Transition Awards provide up to five years of funding in two phases: Phase 1 supports the final years of mentored, postdoctoral training; and Phase 2 supports the independent research of the early career, tenure-track investigators. 

Research projects must be hypothesis-driven, breast cancer-focused studies. They may be considered basic, translational, clinical and/or population science. 

Komen’s research priorities are conquering metastatic and aggressive breast cancers, advancing personalized breast cancer care throughout the continuum of care and eliminating breast cancer disparities and inequities

Eligibility:

  • Individuals pursuing independent breast cancer research careers who are in the final years of mentored postdoctoral research training positions with no more than five years of total postdoctoral research experience at the time of Letter of Intent submission (August 7, 2024). For this application clinical fellows are considered eligible and equal to the postdoctoral rank.
  • Must have a doctoral degree, including M.D., Ph.D., Dr.P.H., D.O., or equivalent.
  • May not hold any appointment designated as faculty (e.g., assistant professor, clinical assistant professor, faculty-level instructor, or equivalent). Clinical fellows with the title instructor are allowed as long as they are no more than 5 years into their training similar to above bullet concerning postdoctoral training.
  • Must be able to devote at least 75% of full-time effort to breast cancer research and activities, i.e., protected research time.
  • Applicant/PI may not hold another career transition award, training award (K-type awards) or R-type award at time of notification of intent to fund (on or around April 15, 2025). If Applicant previously held an R-type award at any point, they are not eligible to apply for this award.
  • Is not required to be a U.S. citizen or permanent resident.

*The University of Arizona Cancer Center (UACC) can nominate up to two applicants but only if at least one of the two nominees identifies as as someone from groups shown to be historically minoritized and marginalized in biomedical research from National Science Foundation data (details outlined in RFA).

For more information please contact UACC-preaward@arizona.edu


Apply to Internal Competition // Limit: 2 // Tickets Available: 2*

Funding Type
Internal Deadline
External Deadline
August 7, 2024
Solicitation Type

2025 Mallinckrodt Grants

Limit: 1 // K. Rhodes  (Immunology)

 

The funds are designed to provide to tenure track faculty members in their first to fourth year, at American Institutions, who hold M.D. and/or Ph.D. degrees, start-up support to move the project forward to the point where R01 or other independent funding can be obtained.  Applicants with current R01 funding should not apply.

Beginning in 2023, the grant provides $75,000 annually for a period of up to three years.  Grants are not renewable.  Institutions may submit one proposal per session.  Interested candidates should work through their sponsored projects office.

Proposals must contain an adequately detailed description of the project to be clearly understandable by the scientific members of the Trustees.  They need not be in the detail requested by the NIH for R01 grants and should not exceed five pages in length.  Additional material can be submitted, but the five-page application should contain the essential information.  References should also be included to support the proposal.  Note that the five page limit is only for the project description.  

A one-two page lay summary must be provided as part of the proposal. Applicants should bear in mind that our Board includes non-scientist members, making this summary of particular importance.  The summary should include the project’s title, and the investigator's contact information.

In addition to the institution providing recognition of an internal selection process resulting in no more than one candidate, (this requires just a sentence that may be included in the letters), the proposal must be accompanied by letters of approval by the Dean of the medical school and/or another senior faculty member or members who can represent the support of the institution and who are acquainted with the qualifications of the applicant and the potential impact of his/her work.

Funding Type
Internal Deadline
External Deadline
08/01/2025
Solicitation Type

2025 Mallinckrodt Grants

Limit: 1 // K. Rhodes  (Immunology)

 

The funds are designed to provide to tenure track faculty members in their first to fourth year, at American Institutions, who hold M.D. and/or Ph.D. degrees, start-up support to move the project forward to the point where R01 or other independent funding can be obtained.  Applicants with current R01 funding should not apply.

Beginning in 2023, the grant provides $75,000 annually for a period of up to three years.  Grants are not renewable.  Institutions may submit one proposal per session.  Interested candidates should work through their sponsored projects office.

Proposals must contain an adequately detailed description of the project to be clearly understandable by the scientific members of the Trustees.  They need not be in the detail requested by the NIH for R01 grants and should not exceed five pages in length.  Additional material can be submitted, but the five-page application should contain the essential information.  References should also be included to support the proposal.  Note that the five page limit is only for the project description.  

A one-two page lay summary must be provided as part of the proposal. Applicants should bear in mind that our Board includes non-scientist members, making this summary of particular importance.  The summary should include the project’s title, and the investigator's contact information.

In addition to the institution providing recognition of an internal selection process resulting in no more than one candidate, (this requires just a sentence that may be included in the letters), the proposal must be accompanied by letters of approval by the Dean of the medical school and/or another senior faculty member or members who can represent the support of the institution and who are acquainted with the qualifications of the applicant and the potential impact of his/her work.

Funding Type
Internal Deadline
External Deadline
08/01/2025
Solicitation Type

2024 Mallinckrodt Grants

Limit: 1 // Next funding cycle August 1st, 2025*

 

Due to an update in the guidelines, the foundation will not accept proposals during 2024. If still eligible, the PI selected for 2024 will be submitted during 2025.

PI Selected: K. Rhodes  (Immunology)

 

 

The funds are designed to provide to tenure track faculty members in their first to fourth year, at American Institutions, who hold M.D. and/or Ph.D. degrees, start-up support to move the project forward to the point where R01 or other independent funding can be obtained.  Applicants with current R01 funding should not apply.

Beginning in 2023, the grant provides $75,000 annually for a period of up to three years.  Grants are not renewable.  Institutions may submit one proposal per session.  Interested candidates should work through their sponsored projects office.

Proposals must contain an adequately detailed description of the project to be clearly understandable by the scientific members of the Trustees.  They need not be in the detail requested by the NIH for R01 grants and should not exceed five pages in length.  Additional material can be submitted, but the five-page application should contain the essential information.  References should also be included to support the proposal.  Note that the five page limit is only for the project description.  

A one-two page lay summary must be provided as part of the proposal. Applicants should bear in mind that our Board includes non-scientist members, making this summary of particular importance.  The summary should include the project’s title, and the investigator's contact information.

In addition to the institution providing recognition of an internal selection process resulting in no more than one candidate, (this requires just a sentence that may be included in the letters), the proposal must be accompanied by letters of approval by the Dean of the medical school and/or another senior faculty member or members who can represent the support of the institution and who are acquainted with the qualifications of the applicant and the potential impact of his/her work.

Funding Type
Internal Deadline
External Deadline
08/01/2024
Solicitation Type

HSRA HRSA-24-098: 2024 Nurse Education, Practice, Quality and Retention (NEPQR) – Workforce Expansion Program (WEP)

Limit: 1 // C. Lacasse ( College of Nursing - Teaching/ Learning Practice and Evaluation)

 

*This is a Forecasted Opportunity.

Estimated Post Date: Jun 03, 2024
Estimated Application Due Date: Jul 15, 2024

The purpose of the Nurse Education, Practice, Quality, and Retention (NEPQR)-Workforce Expansion Program (WEP) is to increase the nursing workforce in rural (non-metro) and underserved areas to address the critical shortage of nurses, specifically in acute and long-term care settings. 

Funding Type
Internal Deadline
External Deadline
07/15/2024*

HRSA HRSA-25-085: 2024 New Access Points

No Applicants  // Limit: 1 // Tickets Available: 1 

 

HRSA will only review your first validated application under HRSA-25-085 in Grants.gov.

 

This Notice of Funding Opportunity (NOFO) announces the opportunity to apply for New Access Points (NAP) funding under the Health Center Program. The purpose of this funding is to support new health center service delivery sites to expand affordable, accessible, and high-quality primary health care for underserved communities and populations. In this NOFO, such sites are referred to as new access points. Award recipients will use NAP funding to provide primary health care services at one or more new access points

Internal Deadline
External Deadline
08/15/2024

HRSA HRSA-24-112: 2024 Rural Maternal Health Data Support and Analysis Program

No Applicants  // Limit: 1 // Tickets Available: 1 

 

HRSA will only review your last validated application before the Grants.gov due date.

This program will fund one entity to provide data support to rural maternal health care networks to assist efforts to improve maternal health care at the community- and regional-levels. This program will also fund the use of data to inform the improvement of rural maternal health care nationwide.

Internal Deadline
External Deadline
07/15/2024

NIH PAR-23-248: 2024 Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)

No applicants // Limit: 1 // Tickets Available: 1 

 

Only one application per institution is allowed. 

The purpose of this notice of funding opportunity is to invite Institutional Network Awards (U2C-TL1) to cultivate a highly integrated cohort of trainees and early career investigators and to develop career development resources to accelerate kidney, urologic, and hematologic research. To maximize integration and promote a true trainee community, Institutions are invited to submit a single, unified U2C-TL1 application to engage, recruit, prepare, and sustain the next generation of scientists able to contribute to advancing research in kidney, urology, and hematology. Applications representing multiple institutions within a single metropolitan area are strongly encouraged (see Section III.3). Successful awardees are expected to relinquish all active T32s supported by the NIDDK, Division of Kidney, Urologic, and Hematologic Diseases (KUH) at the time of the U2C-TL1 award.

Funding Type
Internal Deadline
External Deadline
09/27/2024

NISG RFA-DK-25-003: 2024 Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)

No Applicants // Limit: 1 // Tickets Available: 1 

 

Only one application per institution is allowed.

 

 

This Notice of Funding Opportunity (NOFO) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK.  The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission.  DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.  Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding. 

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Funding Type
Internal Deadline
External Deadline
10/23/2024